2025-04-24 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Review

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance against the S&P 500 (VOO), considering its recent price movements, financial statements, and key indicators.  LLY shows significantly higher returns than the S&P 500, though with increased volatility as indicated by its higher beta and MDD.


**1. Performance Comparison with S&P 500:**

Eli Lilly and Co. is a major pharmaceutical company developing and manufacturing medicines and biological products.

* **Cumulative Return (LLY):** 308.74%
* **Cumulative Return (VOO):** 78.93%
* **Return Difference:** 229.8%
* **Relative Divergence:** 70.2% (This indicates LLY's performance is in the 70.2nd percentile relative to its historical performance against the S&P 500. It is *not* a direct comparison to the S&P 500 return. )

The table below shows Alpha and Beta analysis across various years, indicating LLY's outperformance (positive Alpha) and higher volatility (higher Beta) compared to the market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 141.0% | 76.8% | 123.0% | 0.2 | 744.8 |


**2. Recent Price Movement:**

* **Closing Price:** $829.42
* **5-Day Moving Average:** $809.97
* **20-Day Moving Average:** $783.30
* **60-Day Moving Average:** $832.69

The price is above the 5-day and 20-day moving averages, suggesting a short-term uptrend. However, it's slightly below the 60-day moving average, indicating some potential resistance.  The small daily change of $0.23 doesn't signal a significant price jump or drop.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4174 (Medium Risk)
* **RSI:** 51.58 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 1.46 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +1.4 (Short-term upward trend)
* **Expected Return:** 82.4% (This is a significant long-term expected return over the S&P 500.  It's crucial to understand what factors drive this forecast and associated risk).


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-10-30 | $1.08  | $11.44 B    |
| 2024-08-08 | $3.29  | $11.30 B    |
| 2024-04-30 | $2.49  | $8.77 B     |
| 2023-11-02 | -$0.06 | $9.50 B     |
| 2024-10-30 | -$0.06 | $9.50 B     |

There appears to be a duplicate entry for October 30, 2024.  Assuming this is an error, the data shows fluctuating EPS and relatively consistent revenue.  Further investigation is needed to determine the reasons behind the EPS volatility.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |
| 2023-12-31 | $9.35B    | 80.88%        |

Revenue shows a significant increase in Q4 2024. Profit margins remain consistently high across the quarters.

**Capital and Profitability:**

| Quarter | Equity     | ROE       |
|---------|------------|-----------|
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |
| 2024-03-31 | $12.81B   | 17.51%    |
| 2023-12-31 | $10.77B   | 20.33%    |

Equity shows an upward trend, while ROE fluctuates, indicating variations in profitability relative to shareholder equity.


**6. Overall Analysis:**

LLY has significantly outperformed the S&P 500 over the analyzed period, exhibiting substantial growth. However, this superior performance comes with higher volatility (higher Beta and MDD). The recent price movements suggest a short-term upward trend, supported by positive technical indicators like PPO. While financial statements show strong revenue and high profit margins, fluctuating EPS requires further investigation. The high projected long-term return is promising but necessitates a thorough understanding of the underlying assumptions and associated risks before making any investment decisions.  A deeper dive into the drivers of the projected 82.4% return and a careful examination of the company's product pipeline and competitive landscape are essential for a complete assessment.
